Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 14/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078736 | 0.90 | GBA1 (0.47) | KDM4EHSD17B10ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL4072993 | 0.90 | KDM4E (0.53) | KDM4EHSD17B10ALDH1A1TSHRLMNA | |
| SCHEMBL4072879 | 0.88 | ALDH1A1 (0.50) | KDM4EHSD17B10ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL4075936 | 0.87 | KDM4E (0.55) | KDM4EHSD17B10ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL5455857 | 0.87 | ALDH1A1 (0.45) | KDM4EHSD17B10ALDH1A1LMNAKMT2A | |
| SCHEMBL4071107 | 0.86 | ALDH1A1 (0.45) | KDM4EHSD17B10ALDH1A1LMNAMAPT | |
| SCHEMBL4074128 | 0.86 | ALDH1A1 (0.45) | KDM4EHSD17B10ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL5450427 | 0.86 | ALDH1A1 (0.45) | KDM4EHSD17B10ALDH1A1LMNAMAPT | |
| SCHEMBL4075260 | 0.84 | HSD17B10 (0.53) | KDM4EHSD17B10ALDH1A1TSHRLMNA | |
| SCHEMBL5444484 | 0.84 | ALDH1A1 (0.53) | KDM4EHSD17B10ALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040711-A2 | 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | Amphora Discovery Corporation (US) | 2009-04-01 | — | — | EP | claimed |
| US-20070287706-A1 | Certain substituted quinolones, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2007-12-13 | — | — | US | claimed |
| WO-2007136592-A2 | 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | AMPHORA DISCOVERY CORPORATION (US) | 2007-11-29 | — | — | WO | claimed |
| EP-2040711-A2 | 2-OXO-1,2-DIHYDROQUINOLINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | Amphora Discovery Corporation (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20070287706-A1 | Certain substituted quinolones, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2007-12-13 | — | — | US | disclosed |
| WO-2007136592-A2 | 2-0X0-L,2-DIHYDR0QUIN0LINE DERIVATIVES, COMPOSITIONS, AND USES THEREOF AS ANTIPROLIFERATIVE AGENTS | AMPHORA DISCOVERY CORPORATION (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287706-A1 | Certain substituted quinolones, compositions, and uses thereof | ABCG2, ATP5ME, ATP5MG | KDM4E 2403/4885HSD17B10 1580/4885ALDH1A1 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.